Pharmaceuticals News

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for...

WELLESLEY HILLS, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases,...

Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences

Highlights Fortrea enters into a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical TrialsIncludes a 60,000 sq. ft. GLP bioanalytical lab in Austin; a 200-bed...

WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients...

NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a leading global lifestyle and consumer packaged goods company, in partnership with The...

SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of...

ENIGMA-TRS 1 is a Phase 3 international, one-year, randomized, double-blind, placebo-controlled study in 600+ patients; 12-week study results expected in Q1 2027 Evenamide, a first-in-class glutamate...

CHICAGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced that members of...

Dr. Røpcke joins Resalis with extensive experience in clinical drug development as well as expertise in obesity and cardiometabolic therapy areas Torino, Italy, September 2, 2026 – Resalis...